Products | GSM indications | Breast cancer effects |
---|---|---|
Estrogen products | ||
17-beta estradiol vaginal cream (Estrace) | Moderate to severe vulvar and vaginal atrophy due to menopause | All estrogen products have the following labeling notes: WHI: Estrogen alone was not associated with increased risk of breast cancer; estrogen plus progestin increased the risk Contraindication: known, suspected, or history of breast cancer Warning: Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration |
Conjugated estrogen vaginal cream (Premarina) | Moderate to severe dyspareunia due to menopause Atrophic vaginitis and kraurosis vulvae | |
17-beta estradiol vaginal ring (Estring) | Moderate to severe vulvar and vaginal atrophy due to menopause | |
Estradiol hemihydrate vaginal tablets (Vagifem, Yuvafemb) | Atrophic vaginitis due to menopause | |
Estradiol vaginal inserts (Imvexxy) | GSM, dyspareunia | |
Combination estrogen product | ||
Conjugated estrogens/bazedoxifene (Duavee) | Moderate to severe vasomotor symptoms associated with menopause | |
Nonestrogen products | ||
Prasterone vaginal tablet (Intrarosa; contains dehydroepiandrosterone) | Moderate to severe dyspareunia due to menopause | Warning: Prasterone is contraindicated in women with known or suspected breast cancer; prasterone has not been studied in women with a history of breast cancer |
Ospemifene (Osphena) oral tablet | Moderate to severe dyspareunia due to menopause | Warning: Ospemifene has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer or with a history of breast cancer |